



UTTAR PRADESH MEDICAL SUPPLIES CORPORATION LTD.

(A Government of Uttar Pradesh Undertaking)

Regd. Office: SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226 010

Corrigendum-1 date 17-09-2024

With reference to tender no. UPMSC/Drugs-219/11, dated 27/08/2024 a corrigendum is being issued as follows:

A) Date Corrigendum

Reference of Tender Document	Existing Date	Revised Date
Last Date and Time for Online Submission of Tender	19 September 2024	26 September 2024 UPTO 15:00 Hrs
Date and Time of Opening of Technical BID-COVER 'A'	19 September 2024 UPTO 15:00 Hrs	26 September 2024 UPTO 15:30 Hrs

B) Technical corrigendum

Reference of Tender Document	Existing Tender Condition	Clarification/ Revised Tender Condition												
DESCRIPTION, DIRECTIVE & ABBREVIATIONS Page No - 17	The Validity of Contract: 31-Oct-2024	The Validity of Contract: One year												
DESCRIPTION, DIRECTIVE & ABBREVIATIONS Page No - 67	Supply Commitment quantity during rate contract period (04 month)	Supply Commitment quantity during rate contract period (01 year)												
ANNEXURE – A Schedule of Requirement Page No - 35	1- Anti Rabies Serum- Human	<table border="1"><thead><tr><th>Key Parameters</th><th>Detailed Description</th></tr></thead><tbody><tr><td>Active ingredient:</td><td>Human rabies immunoglobulin</td></tr><tr><td>PHARMACOTHERAPEUTIC GROUP</td><td>Immune sera and immunoglobulins specific human rabies immunoglobulin</td></tr><tr><td>QUALITATIVE AND QUANTITATIVE COMPOSITION per 1 ml</td><td>Human protein 100 – 170 mg, there of immunoglobulin at least 95 percent with antibodies to rabies virus at least or not less than 150 IU per ml</td></tr><tr><td>Pharmaceutical form</td><td>Solution for injection for intramuscular use. Clear solution.</td></tr><tr><td>THERAPEUTIC INDICATIONS:-</td><td>Post-exposure prophylaxis of rabies infection after grave bite or CAT -III bites</td></tr></tbody></table>	Key Parameters	Detailed Description	Active ingredient:	Human rabies immunoglobulin	PHARMACOTHERAPEUTIC GROUP	Immune sera and immunoglobulins specific human rabies immunoglobulin	QUALITATIVE AND QUANTITATIVE COMPOSITION per 1 ml	Human protein 100 – 170 mg, there of immunoglobulin at least 95 percent with antibodies to rabies virus at least or not less than 150 IU per ml	Pharmaceutical form	Solution for injection for intramuscular use. Clear solution.	THERAPEUTIC INDICATIONS:-	Post-exposure prophylaxis of rabies infection after grave bite or CAT -III bites
Key Parameters	Detailed Description													
Active ingredient:	Human rabies immunoglobulin													
PHARMACOTHERAPEUTIC GROUP	Immune sera and immunoglobulins specific human rabies immunoglobulin													
QUALITATIVE AND QUANTITATIVE COMPOSITION per 1 ml	Human protein 100 – 170 mg, there of immunoglobulin at least 95 percent with antibodies to rabies virus at least or not less than 150 IU per ml													
Pharmaceutical form	Solution for injection for intramuscular use. Clear solution.													
THERAPEUTIC INDICATIONS:-	Post-exposure prophylaxis of rabies infection after grave bite or CAT -III bites													

		<table border="1"> <tr> <td>Virus safety</td> <td>Should not contain rabies & other virus particle that may immunogenic and produce on toward effects on recipient immunity.</td> </tr> <tr> <td>Pregnancy and lactation</td> <td>The safety for use in human pregnancy and lactation should be established & there should be no harmful effects on the course of pregnancy, on the foetus or the neonate.</td> </tr> <tr> <td>Effects on ability to drive and use machines</td> <td>No effects on the ability to drive and use machines.</td> </tr> <tr> <td>STORAGE AND STABILITY</td> <td>To be stored at +2 °C to +8 °C (refrigerator). Shelf life should not be less than two years.</td> </tr> <tr> <td>CONTRAINDICATIONS</td> <td>There should be no contraindications to the administration of rabies immunoglobulin.</td> </tr> <tr> <td>INTERACTIONS WITH OTHER MEDICINAL PRODUCTS</td> <td>There should be no harmful interaction with other medicines.</td> </tr> <tr> <td>Approvals</td> <td>DCGI approved</td> </tr> </table>	Virus safety	Should not contain rabies & other virus particle that may immunogenic and produce on toward effects on recipient immunity.	Pregnancy and lactation	The safety for use in human pregnancy and lactation should be established & there should be no harmful effects on the course of pregnancy, on the foetus or the neonate.	Effects on ability to drive and use machines	No effects on the ability to drive and use machines.	STORAGE AND STABILITY	To be stored at +2 °C to +8 °C (refrigerator). Shelf life should not be less than two years.	CONTRAINDICATIONS	There should be no contraindications to the administration of rabies immunoglobulin.	INTERACTIONS WITH OTHER MEDICINAL PRODUCTS	There should be no harmful interaction with other medicines.	Approvals	DCGI approved
Virus safety	Should not contain rabies & other virus particle that may immunogenic and produce on toward effects on recipient immunity.															
Pregnancy and lactation	The safety for use in human pregnancy and lactation should be established & there should be no harmful effects on the course of pregnancy, on the foetus or the neonate.															
Effects on ability to drive and use machines	No effects on the ability to drive and use machines.															
STORAGE AND STABILITY	To be stored at +2 °C to +8 °C (refrigerator). Shelf life should not be less than two years.															
CONTRAINDICATIONS	There should be no contraindications to the administration of rabies immunoglobulin.															
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS	There should be no harmful interaction with other medicines.															
Approvals	DCGI approved															

All other terms & conditions of the tender document shall remain same.

**MANAGING DIRECTOR
UPMSCL**